Last reviewed · How we verify
NCT05569824: LFD-AsPaeds
LFD of Aspergillus Antigen in Paediatrics
trial testing Lateral-flow Device in Invasive Pulmonary Aspergillosis in 20 participants. Status unknown.
19 January 2024
Quick facts
| Lead sponsor | St George's University Hospitals NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 10 June 2022 |
| Primary completion | 19 January 2024 |
| Estimated completion | 29 April 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Lateral-flow Device
Conditions studied
- Invasive Pulmonary Aspergillosis — all drugs for Invasive Pulmonary Aspergillosis →
- Invasive Fungal Disease — all drugs for Invasive Fungal Disease →
Sponsor
St George's University Hospitals NHS Foundation Trust
Who can join
Under 18, any sex, with Invasive Pulmonary Aspergillosis or Invasive Fungal Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Many children and young people are at risk of invasive fungal disease (IFD), such as those who have had a haematopoietic stem cell transplants, those with an immune deficiency or those who are prescribed immunosuppressive drugs, for example, corticosteroids. One type of mould that causes invasive fungal disease is called Aspergillus. There is currently no quick test which can tell us if someone has an invasive fungal disease caused by Aspergillus called Aspergillosis. It is a difficult condition to diagnose and the results from the tests that are involved take days or weeks to come back. These tests including a few different blood tests, a scan of the lungs (CT scans) and taking fluid from inside the lungs/airway. A new test for Aspergillosis is the lateral flow device (LFD) assay. This is a rapid test which gives a result within minutes. It involves testing a sample of the fluid from the lungs/airway. This fluid can be obtained as part of the routine investigations for Aspergillosis. It has been shown to be a good and safe test in adults but the investigators do not know if it will be a valuable test in children and young people yet. The purpose of this study is to determine whether the LFD test can effectively diagnose Aspergillosis in children and young people.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05569824
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Invasive Pulmonary Aspergillosis
Currently open trials in the same condition.
- NCT07238114 — Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors · active not recruiting
- NCT06537726 — Breath Analysis for the Detection of Invasive Fungal Infections · recruiting
- NCT05860387 — Early Diagnosis of Invasive Lung Aspergillosis · recruiting
Other St George's University Hospitals NHS Foundation Trust trials
Trials by the same sponsor.
- NCT04416347 — COVID19 Clinical Predictors and Outcome · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05569824 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St George's University Hospitals NHS Foundation Trust
- Last refreshed: 13 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05569824.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing